Acetylcholinesterase inhibition, molecular docking and ADME prediction studies of new dihydrofuran-piperazine hybrid compounds

SARI S., YILMAZ M.

MEDICINAL CHEMISTRY RESEARCH, cilt.30, sa.11, ss.2114-2126, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Sayı: 11
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1007/s00044-021-02788-5
  • Dergi Adı: MEDICINAL CHEMISTRY RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, Veterinary Science Database
  • Sayfa Sayıları: ss.2114-2126
  • Anahtar Kelimeler: Piperazine, Dihydrofuran, Radical cyclization, Acetylcholinesterase inhibition, Molecular docking, ADME, MANGANESE(III) ACETATE, QUINOLINONE DERIVATIVES, RADICAL CYCLIZATIONS, ESTIMATE SOLUBILITY, DRUG DISCOVERY, ALZHEIMERS, DESIGN, 3-OXOPROPANENITRILES, PERMEABILITY, DONEPEZIL
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Novel acrylamide and methacryloyl carrying piperazine-dihydrofuran derivatives (3a-p) were designed and obtained from radical cyclizations of unsaturated piperazine derivatives (1a-f) with 1,3-dicarbonyl compounds (2a-c) mediated by Mn(OAc)(3). Obtained compounds were characterized by spectroscopic methods. In vitro AChE inhibitory activites of 3a-p were evaluated against AChE (Acetylcholinesterase) by Ellman method and test results showed that 3a, 3c, 3j, and 3l are the most active AChEI's (AChE inhibitors) of our work with IC50 (half-maximal inhibitory concentration) values of 2.62, 5.29, 1.17, and 3.90 mu M, respectively. Furthermore, ligand-protein interactions and inhibitory activity mechanisms of 3a and 3j were investigated by molecular docking. Finally, in silico molecular property and ADME predictions (absorption, distribution, metabolism and excretion) of potential AChEI's were predicted by PreADMET and Molinspiration webservers. It can be concluded that the lead compound 3j show excellent inhibiton and satisfactory druglike characteristics.